<DOC>
	<DOCNO>NCT00969410</DOCNO>
	<brief_summary>A pharmacodynamic study evaluate effect AV-299 exploratory pharmacodynamic marker subject advance solid tumor liver metastasis . To evaluate safety tolerability AV-299 administer IV subject advance solid tumor liver metastasis .</brief_summary>
	<brief_title>A Pharmacodynamic Study AV-299 ( Formerly SCH 900105 ) Subjects With Advanced Solid Tumors Who Have Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Ability give write informed consent able adhere dose visit schedule . Diagnosis advance colorectal , breast , gastric/esophageal pancreatic cancer liver metastases amenable biopsy . Histological cytological evidence malignancy . Advanced metastatic colorectal , breast , gastric/esophageal pancreatic cancer recur progress follow standard therapy fail standard therapy ; standard therapy currently exist , subject candidate , unwilling undergo standard therapy . Note : Additional tumor histology may eligible base available HGF/cMet pathway data approval Sponsor . Disease currently amenable curative surgical intervention . Male female ≥ 18 year age . ECOG performance status 01 . Measurable pMet immunohistochemistry archive otherwise available tumor sample . Female subject childbearing potential must negative pregnancy test within 5 day prior first dose study drug . Female subject childbearing potential male subject whose sexual partner childbearing potential must agree abstain sexual intercourse use effective method contraception study 60 day last dose AV299 ( formerly SCH 900105 ) . Examples effective method contraception include oral contraceptive double barrier method condom plus spermicide condom plus diaphragm . Adequate hematologic function evidence Hg ≥ 9g/dL , WBC ≥ 3000 per mm3 , ANC ≥ 1500 per mm3 platelet count ≥ 100,000 per mm3 . Adequate hepatic function evidence serum bilirubin level ≤ 1.5 × ULN ( except know Gilbert 's Syndrome ) serum AST/ALT level ≤ 5 × ULN . Adequate renal function evidence serum creatinine level ≤ 1.5 × ULN calculate creatinine clearance &gt; 60 mL/min . Adequate coagulation function evidence PTT ≤ 1.5 × ULN INR ≤ 1.5 × ULN . Recovery effect prior surgery , radiotherapy , systemic antineoplastic therapy . Subjects abnormal liver function test ( LFTs ) screen Hepatitis B C within past 6 month prior study enrollment , need screen Hepatitis B C enrol screen negative . Women breastfeed , pregnant , intend become pregnant . Hematologic malignancy . Any follow within 6 month prior administration study drug : Myocardial infarction ( MI ) , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack seizure disorder . Serious/symptomatic active infection , infection require antibiotic , within 14 day prior first dose study drug . Persistent , unresolved CTCAE v3.0 Grade 2 high drugrelated toxicity ( except alopecia , erectile dysfunction , hot flash , decrease libido , Grade 2 sensory peripheral neuropathy ) associate previous treatment . Inadequate recovery prior surgical procedure major surgical procedure perform within 4 week prior administration first dose study drug . Any medical psychiatric condition , opinion investigator , might interfere subject 's participation trial interfere interpretation trial result . Known Human Immunodeficiency Virus ( HIV ) infection know HIVrelated malignancy . Known active hepatitis B C. Known hypersensitivity component SCH 900105 . Known bleeding diathesis . Radiotherapy within 3 week prior first study drug administration . Inability comply protocol requirement , include inability undergo liver biopsy . Participation clinical trial involve therapeutic agent . Any medication prohibit study . Active alcohol illicit drug abuse . Stem cell/bone marrow transplant within 6 month first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Neoplasm metastasis</keyword>
	<keyword>Liver neoplasm</keyword>
	<keyword>Neoplastic process</keyword>
	<keyword>Pathologic process</keyword>
	<keyword>Digestive system neoplasm</keyword>
	<keyword>Neoplasms site</keyword>
	<keyword>Digestive system disease</keyword>
	<keyword>Liver disease</keyword>
</DOC>